Endoplast ApS: Financial statements 2023
CVR: 40866442
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Endoplast ApS (CVR 40866442) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 111,350 and a net result of DKK 54,098 compared with DKK -375,524 the year before. Equity in the 2023 report amounted to DKK -349,476.
- Gross Profit
- DKK 111,350
- Profit/Loss
- DKK 54,098
- Equity
- DKK -349,476
- Total Assets
- DKK 364,648
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 111 t. | 54 t. | -349 t. | 0 |
| 2022 | - | -463 t. | -376 t. | -404 t. | 0 |
| 2021 | - | -109 t. | -89 t. | -28 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Endoplast ApS has published its annual report for 2022. Gross profit came to DKK -462,598, and the net result was DKK -375,524.
About Endoplast ApS
Endoplast ApS is a Danish company of the type Anpartsselskab based in Hårlev, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Thomas Foldberg. The company is owned by TACC Holding ApS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK 168,968 and a net result of DKK 99,945 compared with DKK -19,064 the year before. Equity in the 2025 report amounted to DKK -268,595.